Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for anterior chronic exertional compartment syndrome
NL-OMON61731Phase 3Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in Chronic Exertional Compartment Syndrome (CECS) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary outcome measure. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Chronic Exertional Compartment Syndrome (CECS)
Beyond the preview
Go deeper on NL-OMON61731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61731.